201 related articles for article (PubMed ID: 27239054)
1. Hydrocortisone use in ventilated extremely preterm infants decreased bronchopulmonary dysplasia with no effects on neurodevelopment after two years.
Renault A; Patkaï J; Dassieu G; El Ayoubi M; Canouï-Poitrine F; Durrmeyer X
Acta Paediatr; 2016 Sep; 105(9):1047-55. PubMed ID: 27239054
[TBL] [Abstract][Full Text] [Related]
2. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age.
Baud O; Trousson C; Biran V; Leroy E; Mohamed D; Alberti C;
JAMA; 2017 Apr; 317(13):1329-1337. PubMed ID: 28384828
[TBL] [Abstract][Full Text] [Related]
3. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.
Baud O; Maury L; Lebail F; Ramful D; El Moussawi F; Nicaise C; Zupan-Simunek V; Coursol A; Beuchée A; Bolot P; Andrini P; Mohamed D; Alberti C;
Lancet; 2016 Apr; 387(10030):1827-36. PubMed ID: 26916176
[TBL] [Abstract][Full Text] [Related]
4. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial.
Onland W; Cools F; Kroon A; Rademaker K; Merkus MP; Dijk PH; van Straaten HL; Te Pas AB; Mohns T; Bruneel E; van Heijst AF; Kramer BW; Debeer A; Zonnenberg I; Marechal Y; Blom H; Plaskie K; Offringa M; van Kaam AH;
JAMA; 2019 Jan; 321(4):354-363. PubMed ID: 30694322
[TBL] [Abstract][Full Text] [Related]
5. Neurodevelopment at 24 months corrected age in extremely preterm infants treated with dexamethasone alternatives during the late postnatal period: a cohort study.
Melan N; Pradat P; Godbert I; Pastor-Diez B; Basson E; Picaud JC
Eur J Pediatr; 2024 Feb; 183(2):677-687. PubMed ID: 37955745
[TBL] [Abstract][Full Text] [Related]
6. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.
Watterberg KL; Walsh MC; Li L; Chawla S; D'Angio CT; Goldberg RN; Hintz SR; Laughon MM; Yoder BA; Kennedy KA; McDavid GE; Backstrom-Lacy C; Das A; Crawford MM; Keszler M; Sokol GM; Poindexter BB; Ambalavanan N; Hibbs AM; Truog WE; Schmidt B; Wyckoff MH; Khan AM; Garg M; Chess PR; Reynolds AM; Moallem M; Bell EF; Meyer LR; Patel RM; Van Meurs KP; Cotten CM; McGowan EC; Hines AC; Merhar S; Peralta-Carcelen M; Wilson-Costello DE; Kilbride HW; DeMauro SB; Heyne RJ; Mosquera RA; Natarajan G; Purdy IB; Lowe JR; Maitre NL; Harmon HM; Hogden LA; Adams-Chapman I; Winter S; Malcolm WF; Higgins RD;
N Engl J Med; 2022 Mar; 386(12):1121-1131. PubMed ID: 35320643
[TBL] [Abstract][Full Text] [Related]
7. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
Bassler D
Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
[TBL] [Abstract][Full Text] [Related]
8. Neurodevelopmental outcomes of extremely low birthweight infants randomised to different PCO
Thome UH; Genzel-Boroviczeny O; Bohnhorst B; Schmid M; Fuchs H; Rohde O; Avenarius S; Topf HG; Zimmermann A; Faas D; Timme K; Kleinlein B; Buxmann H; Schenk W; Segerer H; Teig N; Bläser A; Hentschel R; Heckmann M; Schlösser R; Peters J; Rossi R; Rascher W; Böttger R; Seidenberg J; Hansen G; Zernickel M; Bode H; Dreyhaupt J; Muche R; Hummler HD;
Arch Dis Child Fetal Neonatal Ed; 2017 Sep; 102(5):F376-F382. PubMed ID: 28087725
[TBL] [Abstract][Full Text] [Related]
9. [The use of postnatal corticosteroid therapy in premature infants to prevent or treat bronchopulmonary dysplasia: current situation and recommendations].
Jarreau PH; Fayon M; Baud O; Autret-Leca E; Danan M; de Verdelhan A; Castot A
Arch Pediatr; 2010 Oct; 17(10):1480-7. PubMed ID: 20864322
[TBL] [Abstract][Full Text] [Related]
10. [Glucocorticoide therapy in premature infants: French practices in 2006].
Autret-Leca E; Bauer S; Alberti C; Jonville-Béra AP; Aujard Y; Bensouda-Grimaldi L; Baud O
Arch Pediatr; 2009 Jul; 16(7):999-1004. PubMed ID: 19410441
[TBL] [Abstract][Full Text] [Related]
11. Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan.
Onland W; Merkus MP; Nuytemans DH; Jansen-van der Weide MC; Holman R; van Kaam AH;
Trials; 2018 Mar; 19(1):178. PubMed ID: 29523175
[TBL] [Abstract][Full Text] [Related]
12. Duration of mechanical ventilation is more critical for brain growth than postnatal hydrocortisone in extremely preterm infants.
Rousseau C; Guichard M; Saliba E; Morel B; Favrais G
Eur J Pediatr; 2021 Nov; 180(11):3307-3315. PubMed ID: 33993400
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial: A Secondary Analysis of a Randomized Clinical Trial.
Gentle SJ; Rysavy MA; Li L; Laughon MM; Patel RM; Jensen EA; Hintz S; Ambalavanan N; Carlo WA; Watterberg K;
JAMA Netw Open; 2023 May; 6(5):e2315315. PubMed ID: 37256621
[TBL] [Abstract][Full Text] [Related]
14. Placental Findings and Effect of Prophylactic Hydrocortisone in Extremely Preterm Infants.
Héneau A; Guimiot F; Mohamed D; Rideau Batista Novais A; Alberti C; Baud O;
Pediatrics; 2018 Feb; 141(2):. PubMed ID: 29348196
[TBL] [Abstract][Full Text] [Related]
15. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children.
Rademaker KJ; Uiterwaal CS; Groenendaal F; Venema MM; van Bel F; Beek FJ; van Haastert IC; Grobbee DE; de Vries LS
J Pediatr; 2007 Apr; 150(4):351-7. PubMed ID: 17382109
[TBL] [Abstract][Full Text] [Related]
16. Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.
Onland W; Offringa M; Cools F; De Jaegere AP; Rademaker K; Blom H; Cavatorta E; Debeer A; Dijk PH; van Heijst AF; Kramer BW; Kroon AA; Mohns T; van Straaten HL; te Pas AB; Theyskens C; van Weissenbruch MM; van Kaam AH
BMC Pediatr; 2011 Nov; 11():102. PubMed ID: 22070744
[TBL] [Abstract][Full Text] [Related]
17. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants.
Watterberg KL; Shaffer ML; Mishefske MJ; Leach CL; Mammel MC; Couser RJ; Abbasi S; Cole CH; Aucott SW; Thilo EH; Rozycki HJ; Lacy CB
Pediatrics; 2007 Jul; 120(1):40-8. PubMed ID: 17606560
[TBL] [Abstract][Full Text] [Related]
18. Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants.
Kersbergen KJ; de Vries LS; van Kooij BJ; Išgum I; Rademaker KJ; van Bel F; Hüppi PS; Dubois J; Groenendaal F; Benders MJ
J Pediatr; 2013 Sep; 163(3):666-71.e1. PubMed ID: 23706359
[TBL] [Abstract][Full Text] [Related]
19. Permissive hypercapnia in extremely low birthweight infants (PHELBI): a randomised controlled multicentre trial.
Thome UH; Genzel-Boroviczeny O; Bohnhorst B; Schmid M; Fuchs H; Rohde O; Avenarius S; Topf HG; Zimmermann A; Faas D; Timme K; Kleinlein B; Buxmann H; Schenk W; Segerer H; Teig N; Gebauer C; Hentschel R; Heckmann M; Schlösser R; Peters J; Rossi R; Rascher W; Böttger R; Seidenberg J; Hansen G; Zernickel M; Alzen G; Dreyhaupt J; Muche R; Hummler HD;
Lancet Respir Med; 2015 Jul; 3(7):534-43. PubMed ID: 26088180
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic postnatal corticosteroids: Early hydrocortisone.
Baud O; Watterberg KL
Semin Fetal Neonatal Med; 2019 Jun; 24(3):202-206. PubMed ID: 31043325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
